[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019014640A - Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas. - Google Patents

Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas.

Info

Publication number
MX2019014640A
MX2019014640A MX2019014640A MX2019014640A MX2019014640A MX 2019014640 A MX2019014640 A MX 2019014640A MX 2019014640 A MX2019014640 A MX 2019014640A MX 2019014640 A MX2019014640 A MX 2019014640A MX 2019014640 A MX2019014640 A MX 2019014640A
Authority
MX
Mexico
Prior art keywords
cas9 nucleases
engineered cas9
variants
engineered
nucleases
Prior art date
Application number
MX2019014640A
Other languages
English (en)
Inventor
Barrett Ethan Steinberg
Derek Cerchione
Original Assignee
Editas Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editas Medicine Inc filed Critical Editas Medicine Inc
Publication of MX2019014640A publication Critical patent/MX2019014640A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a variantes de nucleasa Cas9 y a métodos para producir y usar las variantes.
MX2019014640A 2017-06-09 2018-06-08 Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas. MX2019014640A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517811P 2017-06-09 2017-06-09
US201862665388P 2018-05-01 2018-05-01
PCT/US2018/036695 WO2018227114A1 (en) 2017-06-09 2018-06-08 Engineered cas9 nucleases

Publications (1)

Publication Number Publication Date
MX2019014640A true MX2019014640A (es) 2020-10-05

Family

ID=62779085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014640A MX2019014640A (es) 2017-06-09 2018-06-08 Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas.

Country Status (9)

Country Link
US (3) US10428319B2 (es)
EP (1) EP3635104A1 (es)
JP (2) JP7518620B2 (es)
KR (1) KR20200016892A (es)
CN (1) CN110997908A (es)
AU (1) AU2018279829B2 (es)
CA (1) CA3065813A1 (es)
MX (1) MX2019014640A (es)
WO (1) WO2018227114A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4095263A1 (en) 2017-01-06 2022-11-30 Editas Medicine, Inc. Methods of assessing nuclease cleavage
EP3615672A1 (en) 2017-04-28 2020-03-04 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
KR20200016892A (ko) 2017-06-09 2020-02-17 에디타스 메디신, 인코포레이티드 조작된 cas9 뉴클레아제
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
MA51186A (fr) 2017-12-14 2020-10-21 Bayer Healthcare Llc Matériels et procédés pour traiter la dystrophie des cônes et des bâtonnets autosomique dominante
WO2020163496A1 (en) 2019-02-05 2020-08-13 AMMR Joint Venture Enhanced selection of efficient targeted genome manipulating agents
CA3141721A1 (en) * 2019-07-11 2021-01-14 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
CN112538471B (zh) * 2020-12-28 2023-12-12 南方医科大学 一种CRISPR SpCas9(K510A)突变体及其应用
US20240139319A1 (en) * 2021-02-01 2024-05-02 Epsilen Bio S.R.L Gene silencing
EP4286401A1 (en) * 2022-06-03 2023-12-06 Technische Universität Dresden Use of an artificial protein or of a nucleic acid encoding the artificial protein for providing a functional ribonucleoprotein complex
WO2024147677A1 (ko) * 2023-01-04 2024-07-11 고려대학교 산학협력단 2차 대사산물 증가를 위한 유전자 조작된 cas9 시스템과 이를 이용한 2차 대사산물 증진 방법
CN117866926B (zh) * 2024-03-07 2024-08-16 珠海舒桐医疗科技有限公司 一种CRISPR-FrCas9蛋白突变体及应用

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US7476500B1 (en) 2001-03-19 2009-01-13 President And Fellows Of Harvard College In vivo selection system for enzyme activity
ATE473637T1 (de) 2005-08-26 2010-07-15 Danisco Verwendung der crispr assoziierten gene (cas)
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US8703489B2 (en) 2008-08-22 2014-04-22 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
WO2010054108A2 (en) 2008-11-06 2010-05-14 University Of Georgia Research Foundation, Inc. Cas6 polypeptides and methods of use
WO2011091324A2 (en) 2010-01-22 2011-07-28 The Scripps Research Institute Methods of generating zinc finger nucleases having altered activity
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
KR20170134766A (ko) 2012-05-25 2017-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Rna-유도된 표적 dna 변형 및 전사의 rna-유도된 조절을 위한 방법 및 조성물
WO2013188638A2 (en) 2012-06-15 2013-12-19 The Regents Of The University Of California Endoribonucleases and methods of use thereof
KR20230065381A (ko) 2012-07-25 2023-05-11 더 브로드 인스티튜트, 인코퍼레이티드 유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용
EP2880171B1 (en) 2012-08-03 2018-10-03 The Regents of The University of California Methods and compositions for controlling gene expression by rna processing
CN110643600A (zh) 2012-10-23 2020-01-03 基因工具股份有限公司 用于切割靶dna的系统及其用途
US20160010154A1 (en) 2012-11-30 2016-01-14 The Parkinson's Institute Screening assays for therapeutics for parkinson's disease
US20160017366A1 (en) 2012-12-06 2016-01-21 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
WO2014093479A1 (en) 2012-12-11 2014-06-19 Montana State University Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
ES2701749T3 (es) 2012-12-12 2019-02-25 Broad Inst Inc Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
PL2771468T3 (pl) 2012-12-12 2015-07-31 Broad Inst Inc Inżynieria systemów, metod i zoptymalizowanych kompozycji kierujących dla manipulacji sekwencjami
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
JP6552965B2 (ja) 2012-12-12 2019-07-31 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための改善された系、方法および酵素組成物のエンジニアリングおよび最適化
PL2931898T3 (pl) 2012-12-12 2016-09-30 Le Cong Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi
JP2016505256A (ja) 2012-12-12 2016-02-25 ザ・ブロード・インスティテュート・インコーポレイテッ 配列操作のためのＣＲＩＳＰＲ−Ｃａｓ成分系、方法および組成物
EP2896697B1 (en) 2012-12-12 2015-09-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
JP2016501531A (ja) 2012-12-12 2016-01-21 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作および治療適用のための系、方法および組成物の送達、エンジニアリングおよび最適化
KR20220139433A (ko) 2012-12-17 2022-10-14 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Rna-가이드된 인간 게놈 조작
CN113005148A (zh) 2013-01-16 2021-06-22 爱默蕾大学 Cas9-核酸复合物及其相关用途
DK3620534T3 (da) 2013-03-14 2021-12-06 Caribou Biosciences Inc Crispr-cas sammensætninger af nucleinsyre-targeting nucleinsyrer
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
ES2713503T3 (es) 2013-03-15 2019-05-22 Massachusetts Gen Hospital Uso de nucleasas FOKI guiadas por ARN (RFN) para aumentar la especificidad para la edición del genoma guiada por ARN
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
EP2981617B1 (en) 2013-04-04 2023-07-05 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
EP2997146A4 (en) 2013-05-15 2017-04-26 Sangamo BioSciences, Inc. Methods and compositions for treatment of a genetic condition
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
US11414695B2 (en) 2013-05-29 2022-08-16 Agilent Technologies, Inc. Nucleic acid enrichment using Cas9
WO2014191521A2 (en) 2013-05-29 2014-12-04 Cellectis New compact scaffold of cas9 in the type ii crispr system
EP3004349B1 (en) 2013-05-29 2018-03-28 Cellectis S.A. A method for producing precise dna cleavage using cas9 nickase activity
MY177814A (en) 2013-06-04 2020-09-23 Harvard College Rna-guided transcriptional regulation
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
EP3539573B1 (en) 2013-06-05 2024-02-14 Duke University Rna-guided gene editing and gene regulation
BR112015031611A2 (pt) 2013-06-17 2017-12-12 Massachusetts Inst Technology aplicação, manipulação e otimização de sistemas, métodos e composições para direcionamento e modelação de doenças e distúrbios de células pós-mitóticas
JP6665088B2 (ja) 2013-06-17 2020-03-13 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物
EP3011033B1 (en) 2013-06-17 2020-02-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
CA2915834A1 (en) 2013-06-17 2014-12-24 Massachusetts Institute Of Technology Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
EP3597755A1 (en) 2013-06-17 2020-01-22 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
KR20230122182A (ko) 2013-07-09 2023-08-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 멀티플렉스 rna-가이드된 게놈 조작
RU2704981C2 (ru) 2013-07-10 2019-11-01 Президент Энд Фэллоуз Оф Харвард Коллидж Ортогональные белки cas9 для рнк-направляемой регуляции и редактирования генов
JP6482546B2 (ja) 2013-07-19 2019-03-13 ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニーＬａｒｉｘ Ｂｉｏｓｃｉｅｎｃｅ， Ｌｌｃ 二重対立遺伝子ノックアウトを生成するための方法および組成物
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US20160237455A1 (en) 2013-09-27 2016-08-18 Editas Medicine, Inc. Crispr-related methods and compositions
US9074199B1 (en) 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
EP3080257A1 (en) 2013-12-12 2016-10-19 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
CA2932439A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
US20160312233A1 (en) 2013-12-13 2016-10-27 Cellectis New method of selection of algal-transformed cells using nuclease
WO2015103153A1 (en) 2013-12-31 2015-07-09 The Regents Of The University Of California Cas9 crystals and methods of use thereof
KR20230152175A (ko) 2014-04-18 2023-11-02 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
WO2015188065A1 (en) 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3180426B1 (en) 2014-08-17 2019-12-25 The Broad Institute, Inc. Genome editing using cas9 nickases
AU2015342749B2 (en) 2014-11-07 2022-01-27 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
EP3237615B2 (en) 2014-12-24 2023-07-26 The Broad Institute, Inc. Crispr having or associated with destabilization domains
US20180155708A1 (en) 2015-01-08 2018-06-07 President And Fellows Of Harvard College Split Cas9 Proteins
EP3245232B1 (en) 2015-01-12 2021-04-21 The Regents of The University of California Heterodimeric cas9 and methods of use thereof
EP4257690A3 (en) 2015-01-28 2024-03-27 Caribou Biosciences, Inc. Crispr hybrid dna/rna polynucleotides and methods of use
WO2016141224A1 (en) 2015-03-03 2016-09-09 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
EP3277805A1 (en) 2015-03-31 2018-02-07 Exeligen Scientific, Inc. Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism
WO2016164797A1 (en) 2015-04-08 2016-10-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activatable crispr/cas9 for spatial and temporal control of genome editing
WO2016167300A1 (ja) 2015-04-13 2016-10-20 国立大学法人東京大学 光依存的に又は薬物存在下でヌクレアーゼ活性若しくはニッカーゼ活性を示す、又は標的遺伝子の発現を抑制若しくは活性化するポリペプチドのセット
GB201506509D0 (en) 2015-04-16 2015-06-03 Univ Wageningen Nuclease-mediated genome editing
CN106011104B (zh) 2015-05-21 2019-09-27 清华大学 利用拆分Cas系统进行基因编辑和表达调控方法
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
RU2021120582A (ru) 2015-06-18 2021-09-02 Те Брод Инститьют, Инк. Мутации фермента crispr, уменьшающие нецелевые эффекты
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
EP3436575A1 (en) 2015-06-18 2019-02-06 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017015015A1 (en) 2015-07-17 2017-01-26 Emory University Crispr-associated protein from francisella and uses related thereto
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
KR20240090567A (ko) * 2015-08-28 2024-06-21 더 제너럴 하스피탈 코포레이션 조작된 crispr-cas9 뉴클레아제
EP3350203A4 (en) 2015-09-17 2019-06-26 The Regents of The University of California CAS9 VARIANTS POLYPEPTIDES COMPRISING INTERNAL INSERTIONS
JP2018532402A (ja) 2015-09-24 2018-11-08 クリスパー セラピューティクス アーゲー Ｒｎａプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用
AU2016340078A1 (en) 2015-10-16 2018-04-12 Temple University - Of The Commonwealth System Of Higher Education Methods and compositions utilizing Cpf1 for RNA-guided gene editing
KR20180133374A (ko) 2015-10-22 2018-12-14 더 브로드 인스티튜트, 인코퍼레이티드 타입 vi-b crispr 효소 및 시스템
US12043852B2 (en) * 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
EP3374501B1 (en) 2015-11-11 2023-07-12 Lonza Ltd Crispr-associated (cas) proteins with reduced immunogenicity
WO2017099494A1 (ko) 2015-12-08 2017-06-15 기초과학연구원 Cpf1을 포함하는 유전체 교정용 조성물 및 그 용도
JP6914274B2 (ja) 2016-01-22 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド Ｃｒｉｓｐｒｃｐｆ１の結晶構造
WO2017136335A1 (en) 2016-02-01 2017-08-10 The Regents Of The University Of California Self-inactivating endonuclease-encoding nucleic acids and methods of using the same
US9896696B2 (en) 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
WO2017161068A1 (en) 2016-03-18 2017-09-21 President And Fellows Of Harvard College Mutant cas proteins
US12065667B2 (en) 2016-04-16 2024-08-20 Ohio State Innovation Foundation Modified Cpf1 MRNA, modified guide RNA, and uses thereof
US20210155911A1 (en) 2016-04-19 2021-05-27 The Broad Institute, Inc. Novel crispr enzymes and systems
CA3026110A1 (en) 2016-04-19 2017-11-02 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2017196768A1 (en) 2016-05-09 2017-11-16 President And Fellows Of Harvard College Self-targeting guide rnas in crispr system
US20190345483A1 (en) 2016-05-12 2019-11-14 President And Fellows Of Harvard College AAV Split Cas9 Genome Editing and Transcriptional Regulation
US20190323038A1 (en) 2016-06-17 2019-10-24 Montana State Univesity Bidirectional targeting for genome editing
US11788083B2 (en) 2016-06-17 2023-10-17 The Broad Institute, Inc. Type VI CRISPR orthologs and systems
CA3018430A1 (en) 2016-06-20 2017-12-28 Pioneer Hi-Bred International, Inc. Novel cas systems and methods of use
US10927383B2 (en) 2016-06-30 2021-02-23 Ethris Gmbh Cas9 mRNAs
AU2017302551B2 (en) 2016-07-26 2023-04-27 The General Hospital Corporation Variants of CRISPR from Prevotella and Francisella 1 (Cpf1)
EP3500967A1 (en) 2016-08-17 2019-06-26 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
US11352647B2 (en) 2016-08-17 2022-06-07 The Broad Institute, Inc. Crispr enzymes and systems
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018049077A1 (en) 2016-09-07 2018-03-15 Flagship Pioneering, Inc. Methods and compositions for modulating gene expression
EP3530737A4 (en) 2016-09-13 2020-04-29 Toolgen Incorporated METHOD FOR IDENTIFYING DNA BASE EDITING USING CYTOSINE DEAMINASE
US20190241880A1 (en) 2016-09-13 2019-08-08 Jason Wright Proximity-dependent biotinylation and uses thereof
JP2019532644A (ja) 2016-09-30 2019-11-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｎａ誘導型核酸修飾酵素及びその使用方法
KR20190072548A (ko) 2016-09-30 2019-06-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
US11242542B2 (en) 2016-10-07 2022-02-08 Integrated Dna Technologies, Inc. S. pyogenes Cas9 mutant genes and polypeptides encoded by same
EP3523427A4 (en) 2016-10-07 2020-09-02 Integrated DNA Technologies, Inc. S. PYOGENES AND POLYPEPTIDES MUTANT CAS9 GENES CODED BY SUCH GENES
IT201600102542A1 (it) 2016-10-12 2018-04-12 Univ Degli Studi Di Trento Plasmide e sistema lentivirale contenente un circuito autolimitante della Cas9 che ne incrementa la sicurezza.
KR20240064734A (ko) 2016-10-14 2024-05-13 더 제너럴 하스피탈 코포레이션 후성적으로 조절되는 부위-특이적 뉴클레아제
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
WO2018074979A1 (en) 2016-10-17 2018-04-26 Nanyang Technological University Truncated crispr-cas proteins for dna targeting
US11180778B2 (en) 2016-11-11 2021-11-23 The Regents Of The University Of California Variant RNA-guided polypeptides and methods of use
CA3044101A1 (en) 2016-11-22 2018-05-31 Integrated Dna Technologies, Inc. Crispr/cpf1 systems and methods
US11674128B2 (en) 2016-12-12 2023-06-13 Tsinghua University Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
WO2018109101A1 (en) 2016-12-14 2018-06-21 Wageningen Universiteit Thermostable cas9 nucleases
EP3555275A1 (en) 2016-12-14 2019-10-23 Wageningen Universiteit Thermostable cas9 nucleases
WO2018112451A1 (en) 2016-12-16 2018-06-21 The Rockefeller University Compositions and methods using cas9 with enhanced spacer acquisition function
WO2018119010A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018118968A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Emulsion-based screening methods
EP4095263A1 (en) 2017-01-06 2022-11-30 Editas Medicine, Inc. Methods of assessing nuclease cleavage
IT201700016321A1 (it) * 2017-02-14 2018-08-14 Univ Degli Studi Di Trento Mutanti di cas9 ad alta specificita' e loro applicazioni.
US11111492B2 (en) 2017-03-06 2021-09-07 Florida State University Research Foundation, Inc. Genome engineering methods using a cytosine-specific Cas9
CN110913881A (zh) 2017-03-14 2020-03-24 加利福尼亚大学董事会 工程化crispr cas9免疫隐身
KR20190133699A (ko) 2017-03-24 2019-12-03 큐어백 아게 Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도
WO2018183766A1 (en) 2017-03-29 2018-10-04 Editas Medicine, Inc. Selection methods
CN108690845B (zh) 2017-04-10 2021-04-27 中国科学院动物研究所 基因组编辑系统和方法
WO2018191715A2 (en) 2017-04-14 2018-10-18 Synthetic Genomics, Inc. Polypeptides with type v crispr activity and uses thereof
WO2018195545A2 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
CA3059208A1 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Inducible, tunable, and multiplex human gene regulation using crispr-cpf1
EP3615665A1 (en) 2017-04-24 2020-03-04 DuPont Nutrition Biosciences ApS Novel anti-crispr genes and proteins and methods of use
WO2018213351A1 (en) 2017-05-16 2018-11-22 The Regents Of The University Of California Thermostable rna-guided endonucleases and methods of use thereof
CN110662835B (zh) 2017-05-19 2023-04-28 清华大学 工程化改造用于由增强的指导RNA优化的基因编辑和转录调节的最小化SaCas9 CRISPR/Cas系统
EP3633034A4 (en) 2017-05-31 2021-03-24 The University Of Tokyo MODIFIED Cas9 PROTEIN, AND RELATED APPLICATION
US20200140835A1 (en) 2017-06-06 2020-05-07 The General Hospital Corporation Engineered CRISPR-Cas9 Nucleases
KR20200016892A (ko) 2017-06-09 2020-02-17 에디타스 메디신, 인코포레이티드 조작된 cas9 뉴클레아제
US10392616B2 (en) 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
EP3650540A4 (en) 2017-07-07 2021-03-31 Toolgen Incorporated TARGET-SPECIFIC CRISPR MUTANT
US11208640B2 (en) 2017-07-21 2021-12-28 Arizona Board Of Regents On Behalf Of Arizona State University Modulating human Cas9-specific host immune response
KR20200036025A (ko) 2017-08-15 2020-04-06 인텔리아 테라퓨틱스, 인크. 메신저 리보핵산(mRNA)을 암호화하는 안정화된 핵산
CA3073448A1 (en) 2017-08-23 2019-02-28 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
EP3676378A4 (en) 2017-08-31 2021-06-09 The New York Genome Center PROCEDURES AND COMPOSITIONS USING CRIMP-CPF1 AND PAIRED GUIDE-CRISPR-RNA FOR PROGRAMMABLE GENOMIC DELETIONS
US11530396B2 (en) 2017-09-05 2022-12-20 The University Of Tokyo Modified CAS9 protein, and use thereof
US11713452B2 (en) 2017-09-08 2023-08-01 University Of North Texas Health Science Center Engineered CAS9 variants
US20190218532A1 (en) 2017-09-19 2019-07-18 Massachusetts Institute Of Technology Streptococcus Canis Cas9 as a Genome Engineering Platform with Novel PAM Specificity
AU2018341985A1 (en) 2017-09-26 2020-04-23 The Board Of Trustees Of The University Of Illinois CRISPR/Cas system and method for genome editing and modulating transcription
GB201716590D0 (en) 2017-10-10 2017-11-22 Univ Wageningen Thermostable cas9 nucleases with reduced off-target activity
WO2019083532A1 (en) 2017-10-26 2019-05-02 Excision Biotherapeutics Inc IDENTIFICATION OF GENE EDITION PROTEINS AND GENE EXCISION (TYPE CAS9 AND ARGONAUTE) FROM OTHER ORGANISMS
GB2582100B (en) 2017-11-01 2023-05-17 Univ California CAS12C Compositions and methods of use
US11970719B2 (en) 2017-11-01 2024-04-30 The Regents Of The University Of California Class 2 CRISPR/Cas compositions and methods of use
RU2020117711A (ru) 2017-11-01 2021-12-02 Те Риджентс Оф Те Юниверсити Оф Калифорния КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ CasZ
US20200255858A1 (en) 2017-11-01 2020-08-13 Jillian F. Banfield Casy compositions and methods of use
US20200255829A1 (en) 2017-11-02 2020-08-13 Arbor Biotechnologies, Inc. Novel crispr-associated transposon systems and components
WO2019092505A1 (en) 2017-11-09 2019-05-16 Casebia Therapeutics Llp Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
US20200318086A1 (en) 2017-11-10 2020-10-08 Novozymes A/S Temperature-sensitive cas9 protein
EP3710583A1 (en) 2017-11-16 2020-09-23 Astrazeneca AB Compositions and methods for improving the efficacy of cas9-based knock-in strategies
WO2019126716A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted rna base editing
US20200392473A1 (en) 2017-12-22 2020-12-17 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2019126709A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
WO2019126762A2 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
WO2019168953A1 (en) 2018-02-27 2019-09-06 President And Fellows Of Harvard College Evolved cas9 variants and uses thereof
AU2019236210A1 (en) 2018-03-14 2020-09-10 Arbor Biotechnologies, Inc. Novel CRISPR DNA targeting enzymes and systems
EP4253551A3 (en) 2018-03-14 2024-01-24 Arbor Biotechnologies, Inc. Novel crispr dna and rna targeting enzymes and systems
WO2019183150A1 (en) 2018-03-19 2019-09-26 Casebia Therapeutics Limited Liability Partnership Novel rna-programmable endonuclease systems and uses thereof

Also Published As

Publication number Publication date
US20200056164A1 (en) 2020-02-20
JP7518620B2 (ja) 2024-07-18
EP3635104A1 (en) 2020-04-15
AU2018279829A1 (en) 2020-01-02
US20180355332A1 (en) 2018-12-13
KR20200016892A (ko) 2020-02-17
CN110997908A (zh) 2020-04-10
US20220177861A1 (en) 2022-06-09
JP2020524497A (ja) 2020-08-20
JP2024001075A (ja) 2024-01-09
AU2018279829B2 (en) 2024-01-04
CA3065813A1 (en) 2018-12-13
US11098297B2 (en) 2021-08-24
WO2018227114A1 (en) 2018-12-13
US10428319B2 (en) 2019-10-01

Similar Documents

Publication Publication Date Title
MX2019014640A (es) Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas.
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
PH12020551397A1 (en) Cot modulators and methods of use thereof
ZA201807001B (en) Acrylic acid, and methods of producing thereof
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
ZA201902141B (en) Acid-alpha glucosidase variants and uses thereof
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2024004419A (es) Variantes de alfa-glucosidasa acida y usos de las mismas.
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
MY179341A (en) Method for producing l-amino acids using an alkaliphilic bacteria
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MY190647A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
HK1245337A1 (zh) 活化的甲酰甘氨酸生成酶及其生成和使用方法
GB2569488A (en) PD-1 specific aptamers
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
MX2019002587A (es) Mezclas de defi y taurato amida y procesos de las mismas.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
PL3577070T3 (pl) Sposób wytwarzania półwyrobu i półwyrób wytworzony zgodnie z tym sposobem
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
NZ783086A (en) Concentrated gibberellin solution formulations
WO2019028012A3 (en) METHODS OF USING PEMBROLIZUMAB AND TREBANANIB